172 related articles for article (PubMed ID: 35213015)
21. Targeting Alternative Splicing for Therapeutic Interventions.
Centa JL; Hastings ML
Methods Mol Biol; 2022; 2537():21-36. PubMed ID: 35895256
[TBL] [Abstract][Full Text] [Related]
22. Antisense-Mediated Splice Modulation to Reframe Transcripts.
Titeux M; Turczynski S; Pironon N; Hovnanian A
Methods Mol Biol; 2018; 1828():531-552. PubMed ID: 30171566
[TBL] [Abstract][Full Text] [Related]
23. Antisense-mediated exon skipping: taking advantage of a trick from Mother Nature to treat rare genetic diseases.
Veltrop M; Aartsma-Rus A
Exp Cell Res; 2014 Jul; 325(1):50-5. PubMed ID: 24486759
[TBL] [Abstract][Full Text] [Related]
24. Making antisense of splicing.
Garcia-Blanco MA
Curr Opin Mol Ther; 2005 Oct; 7(5):476-82. PubMed ID: 16248283
[TBL] [Abstract][Full Text] [Related]
25. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene.
Errington SJ; Mann CJ; Fletcher S; Wilton SD
J Gene Med; 2003 Jun; 5(6):518-27. PubMed ID: 12797117
[TBL] [Abstract][Full Text] [Related]
26. Exonic Variants that Affect Splicing - An Opportunity for "Hidden" Mutations Causing Inherited Retinal Diseases.
Sundaresan Y; Banin E; Sharon D
Adv Exp Med Biol; 2023; 1415():183-187. PubMed ID: 37440032
[TBL] [Abstract][Full Text] [Related]
27. Pseudoexon exclusion by antisense therapy in 6-pyruvoyl-tetrahydropterin synthase deficiency.
Brasil S; Viecelli HM; Meili D; Rassi A; Desviat LR; Pérez B; Ugarte M; Thöny B
Hum Mutat; 2011 Sep; 32(9):1019-27. PubMed ID: 21542064
[TBL] [Abstract][Full Text] [Related]
28. A deep intronic mutation in FGB creates a consensus exonic splicing enhancer motif that results in afibrinogenemia caused by aberrant mRNA splicing, which can be corrected in vitro with antisense oligonucleotide treatment.
Davis RL; Homer VM; George PM; Brennan SO
Hum Mutat; 2009 Feb; 30(2):221-7. PubMed ID: 18853456
[TBL] [Abstract][Full Text] [Related]
29. Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation.
Oren YS; Avizur-Barchad O; Ozeri-Galai E; Elgrabli R; Schirelman MR; Blinder T; Stampfer CD; Ordan M; Laselva O; Cohen-Cymberknoh M; Kerem E; Bear CE; Kerem B
J Cyst Fibros; 2022 Jul; 21(4):630-636. PubMed ID: 34972649
[TBL] [Abstract][Full Text] [Related]
30. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
Hanson B; Wood MJA; Roberts TC
RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
[TBL] [Abstract][Full Text] [Related]
31. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.
Wang Q; Yin H; Camelliti P; Betts C; Moulton H; Lee H; Saleh AF; Gait MJ; Wood MJ
J Gene Med; 2010 Apr; 12(4):354-64. PubMed ID: 20235089
[TBL] [Abstract][Full Text] [Related]
32. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle.
Arechavala-Gomeza V; Graham IR; Popplewell LJ; Adams AM; Aartsma-Rus A; Kinali M; Morgan JE; van Deutekom JC; Wilton SD; Dickson G; Muntoni F
Hum Gene Ther; 2007 Sep; 18(9):798-810. PubMed ID: 17767400
[TBL] [Abstract][Full Text] [Related]
33. Antisense-mediated exon inclusion.
Hua Y; Krainer AR
Methods Mol Biol; 2012; 867():307-23. PubMed ID: 22454070
[TBL] [Abstract][Full Text] [Related]
34. Alternative splicing: role of pseudoexons in human disease and potential therapeutic strategies.
Dhir A; Buratti E
FEBS J; 2010 Feb; 277(4):841-55. PubMed ID: 20082636
[TBL] [Abstract][Full Text] [Related]
35. Personalized Development of Antisense Oligonucleotides for Exon Skipping Restores Type XVII Collagen Expression in Junctional Epidermolysis Bullosa.
Ablinger M; Lettner T; Friedl N; Potocki H; Palmetzhofer T; Koller U; Illmer J; Liemberger B; Hainzl S; Klausegger A; Reisenberger M; Lambert J; Van Gele M; Desmet E; Van Maelsaeke E; Wimmer M; Zauner R; Bauer JW; Wally V
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805154
[TBL] [Abstract][Full Text] [Related]
36. Exploring Splicing-Switching Molecules For Seckel Syndrome Therapy.
Scalet D; Balestra D; Rohban S; Bovolenta M; Perrone D; Bernardi F; Campaner S; Pinotti M
Biochim Biophys Acta Mol Basis Dis; 2017 Jan; 1863(1):15-20. PubMed ID: 27639833
[TBL] [Abstract][Full Text] [Related]
37. Potential therapeutic applications of antisense morpholino oligonucleotides in modulation of splicing in primary immunodeficiency diseases.
Du L; Gatti RA
J Immunol Methods; 2011 Feb; 365(1-2):1-7. PubMed ID: 21147113
[TBL] [Abstract][Full Text] [Related]
38. Background splicing as a predictor of aberrant splicing in genetic disease.
D A; Y L; R S; H D; E B; Rm W; I V; L C; N J D
RNA Biol; 2022; 19(1):256-265. PubMed ID: 35188075
[TBL] [Abstract][Full Text] [Related]
39. Doxycycline-controlled splicing modulation by regulated antisense U7 snRNA expression cassettes.
Marquis J; Kämpfer SS; Angehrn L; Schümperli D
Gene Ther; 2009 Jan; 16(1):70-7. PubMed ID: 18701908
[TBL] [Abstract][Full Text] [Related]
40. Exon skipping: a first in class strategy for Duchenne muscular dystrophy.
Niks EH; Aartsma-Rus A
Expert Opin Biol Ther; 2017 Feb; 17(2):225-236. PubMed ID: 27936976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
